Safety of sugammadex for reversal of neuromuscular block / GHM Honing, CH Martini, A Bom, M van Velzen, M Niesters, LPHJ Aarts, A Dahan, M Boon
ABSTRACT Introduction : Sugammadex is a modified cyclodextrin that is able to reverse neuromuscular block induced by aminosteroidal neuromuscular blocking drugs. Compared to reversal with neostigmine, it reverses neuromuscular block quicker and more predictable and without cholinergic side effects. However, there have been concerns about sugammadex ability to bind other drugs and its effects on QT interval and clotting times. In addition, sugammadex might induce hypersensitivity reactions more frequently than initially anticipated. This review summarizes current evidence with regard to these and other safety aspects of sugammadex. Areas covered : This review provides an overview of the efficacy of sugammadex in various patient populations, evaluates potential interactions with other drugs and discusses adverse effects and reactions that have been reported in the literature. Expert opinion : Sugammadex quickly reverses aminosteroid neuromuscular block with less side effects compared to neostigmine. As such, it has the potential to significantly reduce the incidence of residual neuromuscular block and to improve postoperative pulmonary outcome. Current safety concerns mainly focus on hypersensitivity reactions and cardiac arrhythmias. Although the absolute risk for these events is low, ongoing vigilance and research in this area are needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Expert opinion on drug safety - 18(2019), 10, Seite 883-891 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Honing, GHM [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Expert opinion |
|---|
| Umfang: |
1 Online-Ressource (9 p) |
|---|
| doi: |
10.1080/14740338.2019.1649393 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011197714 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011197714 | ||
| 003 | DE-627 | ||
| 005 | 20230720210228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14740338.2019.1649393 |2 doi | |
| 035 | |a (DE-627)KFL011197714 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/14740338.2019.1649393 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Honing, GHM |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of sugammadex for reversal of neuromuscular block |c GHM Honing, CH Martini, A Bom, M van Velzen, M Niesters, LPHJ Aarts, A Dahan, M Boon |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (9 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Introduction : Sugammadex is a modified cyclodextrin that is able to reverse neuromuscular block induced by aminosteroidal neuromuscular blocking drugs. Compared to reversal with neostigmine, it reverses neuromuscular block quicker and more predictable and without cholinergic side effects. However, there have been concerns about sugammadex ability to bind other drugs and its effects on QT interval and clotting times. In addition, sugammadex might induce hypersensitivity reactions more frequently than initially anticipated. This review summarizes current evidence with regard to these and other safety aspects of sugammadex. Areas covered : This review provides an overview of the efficacy of sugammadex in various patient populations, evaluates potential interactions with other drugs and discusses adverse effects and reactions that have been reported in the literature. Expert opinion : Sugammadex quickly reverses aminosteroid neuromuscular block with less side effects compared to neostigmine. As such, it has the potential to significantly reduce the incidence of residual neuromuscular block and to improve postoperative pulmonary outcome. Current safety concerns mainly focus on hypersensitivity reactions and cardiac arrhythmias. Although the absolute risk for these events is low, ongoing vigilance and research in this area are needed | ||
| 653 | |a Expert opinion | ||
| 653 | |a neuromuscular blockade reversal | ||
| 653 | |a rocuronium safety evaluation | ||
| 653 | |a sugammadex | ||
| 700 | 1 | |a Martini, CH |e verfasserin |4 aut | |
| 700 | 1 | |a Bom, A |e verfasserin |4 aut | |
| 700 | 1 | |a van Velzen, M |e verfasserin |4 aut | |
| 700 | 1 | |a Niesters, M |e verfasserin |4 aut | |
| 700 | 1 | |a Aarts, LPHJ |e verfasserin |4 aut | |
| 700 | 1 | |a Dahan, A |e verfasserin |4 aut | |
| 700 | 1 | |a Boon, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d Abingdon, Oxon : Routledge, Taylor & Francis, 2002 |g 18(2019), 10, Seite 883-891 |h Online-Ressource |w (DE-627)KFL000006084 |w (DE-600)2114527-1 |w (DE-576)302969721 |x 1744-764X |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2019 |g number:10 |g pages:883-891 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/14740338.2019.1649393 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2019 |e 10 |h 883-891 | ||